Similares a AERIFY: Phase 3 Data Reveal Challenges, Potential of Itepekimab in COPD

20 vecinos (text_768) · 105 views · HCPLive · Estados Unidos


★	AERIFY: Phase 3 Data Reveal Challenges, Potential of Itepekimab in COPD	HCPLive @hcplivenews	105	Estados Unidos
4	Mepolizumab Add-On Reduces COPD Exacerbations in Triple-Therapy Patients \| ATS 2026	HCPLive @hcplivenews	1.2K	Estados Unidos	88
19	Efdoralprin Alfa Normalizes Alpha-1 Antitrypsin Levels I #ats2026	HCPLive @hcplivenews	548	Estados Unidos	85
20	La Universitat se suma al Dia Europeu de Dèficit d'Alfa-1	Universitat de València @universitatvalencia	481	España	85
14	Inhaled Treprostinil for IPF: TETON-1 Phase 3 Results With Steven Nathan, MD \| ATS 2026	HCPLive @hcplivenews	301	Estados Unidos	86
13	Sotatercept May Improve Right Heart Function in #pulmonaryhypertension	HCPLive @hcplivenews	232	Estados Unidos	86
1	Mixed AERIFY Data May Delay Itepekimab Approval Pathway in COPD, With Klaus F. Rabe, MD, PhD	HCPLive @hcplivenews	198	Estados Unidos	97
11	Efdoralprin Alfa vs Standard of Care in AATD: Phase 2 ElevAATe Results	HCPLive @hcplivenews	156	Estados Unidos	87
16	What the Phase 3 AD109 Data Mean for Sleep Apnea, With Patrick John Strollo, MD	HCPLive @hcplivenews	142	Estados Unidos	86
6	Tezepelumab Reduced Severe Asthma Exacerbations Across Phenotypes \| ATS 2026	HCPLive @hcplivenews	122	Estados Unidos	88
12	Phase 3b ENCORE: ALIS Improves MAC Lung Disease Outcomes \| ATS 2026	HCPLive @hcplivenews	117	Estados Unidos	86
7	Mepolizumab Reduced COPD Hospitalizations in Eosinophilic Disease \| ATS 2026 With Gerard Criner, MD	HCPLive @hcplivenews	113	Estados Unidos	88
10	Sotatercept May Improve RV Function in Group 3 3 Pulmonary Hypertension	HCPLive @hcplivenews	112	Estados Unidos	87
8	Efdoralprin Alfa vs Standard of Care in AATD: Phase 2 ElevAATe Results	HCPLive @hcplivenews	82	Estados Unidos	87
18	SUNRISE: Tezepelumab Shows Meaningful OCS Reduction in Severe Asthma	HCPLive @hcplivenews	78	Estados Unidos	85
5	ATS 2026 Asthma Updates: Tezepelumab, Dupilumab, OCS Reduction & More \| HCPLive Expert Interviews	HCPLive @hcplivenews	70	Estados Unidos	88
9	Tezepelumab Cuts Severe Asthma Exacerbations 70% in Real-World Patients \| ATS 2026	HCPLive @hcplivenews	68	Estados Unidos	87
2	ATS 2026 Pulmonology: AD109, Ralinepag, ALIS, Itepekimab & More \| HCPLive Expert Interviews	HCPLive @hcplivenews	55	Estados Unidos	91
3	SGLT2 Inhibitors May Reduce COPD Readmissions I ATS 2026	HCPLive @hcplivenews	48	Estados Unidos	88
17	Master Session: It's COPD Dammit	Stanford Medicine X @stanfordmedicinex	35	Estados Unidos	86
15	Pegtarazimod Cuts Oxygen Need in Hospitalized COPD Patients \| ATS 2026 \| Gerald Criner, MD	HCPLive @hcplivenews	29	Estados Unidos	86